<DOC>
	<DOC>NCT01179295</DOC>
	<brief_summary>This is an uncontrolled, open-label, non-randomized phase I / pharmacokinetic study of oral BAY86-9766 to investigate the safety, tolerability, pharmacokinetics, and efficacy profiles in Japanese patients with advanced solid tumors</brief_summary>
	<brief_title>Japanese BAY86-9766 Monotherapy Phase I Study</brief_title>
	<detailed_description />
	<criteria>Japanese patients, who are at least 18 years of age at the first screening examination/ visit, with advanced or refractory solid tumors not amenable to standard therapy. Histological or cytological documentation of nonhematologic, malignant solid tumor, excluding primary brain or spinal tumors, with no current involvement in the central nervous system (CNS) At least one measurable lesion or evaluable disease according to response evaluation criteria in solid tumors (RECIST) version 1.1 Eastern cooperative oncology group performance status (ECOGPS) of 0 or 1 Life expectancy of at least 12 weeks Use of any anticancer therapy including chemotherapy, investigational agents or devices and immunotherapy within 4 weeks of the first dose of study medication Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic pressure &gt; 90 mmHg, despite optimal medical management Known human immunodeficiency virus (HIV) infection or chronic active hepatitis B or C Inadequate bone marrow, liver and renal function Inability to swallow oral medications or any condition that could affect the absorption of orally administered drugs Concomitant treatment with cytochrome P450 isoenzymes CYP3A4 inhibitors/inducers, and CYP2C19 inhibitors/ inducers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>MEK inhibitor</keyword>
	<keyword>BAY86-9766</keyword>
	<keyword>RDEA 119</keyword>
	<keyword>Solid tumor</keyword>
</DOC>